HROW
Harrow Health, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$38.54
+0.73%Sep 4, 2026, 20:48 UTC
Harrow, Inc. announced that Randall E. Pollard departed as Chief Accounting Officer and principal accounting officer, effective September 4, 2026, and appointed Andrew R. Boll as principal accounting officer, effective the same date.
Aug 21, 2026, 16:09 UTC
Harrow Inc. announced clinical study results showing its product Iheezo reduces eye-injection discomfort by more than half.
Source:Aug 11, 2026, 01:07 UTC
Harrow reported a Q2 2026 loss of $0.34 per share, missing the Zacks Consensus Estimate of a loss of $0.23, and compared to earnings of $0.24 per share a year ago.
Jul 1, 2026, 11:00 UTC
Samsung Bioepis relaunched BYOOVIZ (ranibizumab-nuna) in the United States in partnership with Harrow.
Jun 10, 2026, 11:00 UTC
Harrow re-launched VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% for vernal keratoconjunctivitis in pediatric eyecare.